After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a ...

Pfizer PFE stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since mid-August The 50-day ...

Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q3 2025 earnings on Oct. 28. Wall Street analysts expect ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer's (NYSE:PFE) stock is up by a considerable 10% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals ...

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate ...

PFE has shown great efforts in operational efficiencies, as observed in the richer profit margins, the expanding cash flows, ...

What happenedShares of Pfizer (NYSE: PFE) were up by 4% as of 12:08 p.m. ET Wednesday. The drugmaker's stock is rising today in response to two separate catalysts.

Bargain hunters appear to be circling back to the beaten-down pharma stock today.

With Pfizer's stock price at a three-year low, however, it might be the perfect time to start building a position (or adding to an established one) in the drugmaker. Here's why.